Calidi Biotherapeutics Inc

CLDI

$0.60

Closing

▼-28.84%

1D

▼-60.46%

YTD

Market cap

$21.19M

52 week high

$13.04

52 week low

$0.50

Volume

31,140

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$21.19M

Analysts' Rating

STRONG BUY

Price Target (Mean)

10

Total Analysts

1

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

0.00%

52 week high

$13.04

52 week low

$0.50

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy delivering a payload to target and kill tumor cells. The Company is engaged in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. It is engaged in developing allogenic stem cell-based delivery platforms designed to deliver a new generation of targeted immunotherapies for the treatment of cancer. These platforms include CLD-101 (NeuroNova) and CLD-201 (SuperNova).